References
- KefalasCHCiociolaAAFDA-Related Matters Committee of the American College of GastroenterologyThe FDA’s generic-drug approval process: similarities to differences from brand-name drugsAm J Gastrenterol2011106610181021
- WeaverCWhalenJRockoffJD webpage on the InternetBiotech drugs still won’t copyWall Street Journal2013 Available from: http://online.wsj.com/article/SB10001424127887323864304578318111144984632.htmlAccessed April 20, 2016
- SilverS webpage on the InternetIndustry Surveys: BiotechnologyStandard & Poor’s; 2013 Available from: https://securingalpha.files.wordpress.com/2014/01/biotechnology-2013.pdfAccessed April 20, 2016
- DoreyEHow the biologics landscape is evolvingClin Pharm20146916
- BlackstoneEFuhrJThe economics of biosimilarsAm Health Drug Benefits20136846947824991376
- Citation Machine [webpage on the Internet]Innovation Over Imitation: High-Cost Biosimilar FOB Development, Slow UptakeGenerics and Biosimilars Initiative Available from: http://www.citationmachine.net/bibliographies/59804304?new=trueAccessed April 20, 2016
- WinegardenW webpage on the InternetThe Economics of Pharmaceutical PricingPacific Research Institute6 Available from: http://www.pacificresearch.org/fileadmin/documents/Studies/PDFs/2013-2015/PhamaPricingF.pdfAccessed April 20, 2016
- SchellekensHThe first biosimilar epoeitin: but how similar is it?Clin J Am Soc Nephrol20083117417818057303
- CamachoLHFrostCPAbellaEMorrowPKWhittakerSBiosimilars 101: considerations for U.S. oncologists in clinical practiceCancer Med20143488989924810680
- U.S. Food and Drug Administration [webpage on the Internet]Draft Guidance on Biosimilar Product Development Available from: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/Biosimilars/default.htmAccessed April 20, 2016
- EpsteinMSEhrenpreisEDKulkarniPMFDA-Related Matters Committee of the American College of GastroenterologyBiosimilars: the need, the challenge, the future: the FDA perspectiveAm J Gastroenterol2014109121856185924957160
- HassanIAleemSSheikhGAnwarPBiologics in dermatology: a brief reviewBJMP201364a629
- KuhlmannMCovicAThe protein science of biosimilarsNephrol Dial Transplant200621suppl 5v4v816959791
- DornerTKayJBiosimilars in rheumatology: current perspectives and lessons learntNat Rev Rheumatol2015111211225486979
- MyslerEScheinbergMBiosimilars in rheumatology: a view from Latin AmericaClin Rheumatol20123191279128022918492
- Castañeda-HernándezGGonzález-RamírezRKayJScheinbergMABiosimilars in rheumatology: what the clinician should knowRMD Open201511e00001026509046
- US Food AdministrationGuidance for Industry: Bioequivalence studies with pharmacokinetic endpoints for drugs submitted under an ANDA Available from: www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM377465.pdfAccessed May 12, 2016
- U.S. Food Administration [webpage on the Internet]Draft Guidelines: Nonproprietary Naming of Biological Products Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM459987.pdfAccessed April 20, 2016
- WeiseMKurkiPWolff-HolzEBielskyMCSchneiderCBiosimilars: the science of extrapolationBlood2014124223191319625298038
- European Medicines Agency [webpage on the Internet]European Assessment Report on Binocrit Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000725/WC500053615.pdfAccessed April 20, 2016
- GuptaVKhaitanBKTherapeutic potential of biosimilars in dermatologyIndian J Dermatol Venereol Leprol201581545145626323679
- RamananSGramppGDrift, evolution, and divergence in biologics and biosimilars manufacturingBioDrugs201428436337224567263
- MaydenKDLarsonPGeigerDWatsonHBiosimilars in the United States: considerations for oncology advanced practitionersJ Adv Pract Oncol20156210811626649244
- WHO [webpage on the Internet]Guidelines on Evaluation of Similar Biotherapeutic Products (SBPs); 2009 Available from: http://www.who.int/biologicals/areas/biological_therapeutics/BIOTHERAPEU-TICS_FOR_WEB_22APRIL2010.pdfAccessed April 20, 2016
- JelkmannWBiosimilar epoetins and other “follow-on” biologics: update on the European experiencesAm J Hematol2010851077178020706990
- NCSL [webpage on the Internet]State Laws and Legislation Related to Biologic Medications and Substitution of BiosimilarsNational Conference of State Legislature2014 Available from: http://www.ncsl.org/research/health/state-laws-and-legislation-related-to-biologic-medications-and-substitution-of-biosimilars.aspxAccessed April 20, 2016
- PuigLBiosimilars in dermatology: Starting with infliximabActas Dermosifiliogr2013104317518023218608
- GraserD webpage on the InternetIndustry voices: biosimilars and trade secretsFierceBiotech2012 Available from: www.fiercebiotech.com/story/industry-voices-biosimilars-and-trade-secrets/2012-10-24Accessed April 20, 2016
- SocinskiMCuriglianoGJacobsIGumbinerBMacDonaldJThomasDClinical considerations for the development of biosimilars in oncologyMAbs20157228629325621390
- WeiseMBielskyMCDe SmetKBiosimilars: what clinicians should knowBlood2012120265111511723093622
- MellstedtHNiederwieserDLudwigHThe challenge of biosimilarsAnn Oncol200819341141917872902